Published in Blood Weekly, August 9th, 2001
"Cross-resistance between different classes of antineoplastic agents can jeopardize successful combination cancer chemotherapy," according to Kourosh Lotfi and colleagues at the Faculty of Health Sciences in Linkoping and other institutions.
After examining malignant cells refractory to several of the most commonly used anticancer drugs, Lotfi and coworkers found that these cells had higher levels of enzymes that deactivate nucleotides and decreased levels of DNA-splicing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.